long-acting GLP-1RAs on AMD, long-acting agents are known to be more effective in terms of glycemic control and body weight, and it has been suggested that weight-loss mediated pathways may drive the ocular benefits associated with GLP-1RA use. However, they pointed out that this study cohort was matched for hemoglobin A1c and BMI, which decreases the likelihood that the more pronounced benefit associated with long-term agents is due to these factors alone. Moreover, in obese and non-obese individuals, GLP-1 agonist therapy exhibited comparable reduced risks of dry (21% vs
Current NHS challenges: Demand for GLP-1 receptor agonists substantially exceeds supply, with many NHS areas implementing waiting lists or restrictive prescribing policies
The whoosh effect, where weight remains stable for weeks then drops several pounds suddenly, is particularly common during Retatrutide treatment
It also breaks down muscle for energy, especially when: Protein intake is insufficient Resistance training stimulus is absent Weight loss is too rapid Caloric deficit is too aggressive The Protein Paradox Here's where many GLP-1 users get stuck: you need more protein during weight loss, but GLP-1s make it harder to eat protein
Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes